ESCRS postoperative endophthalmitis study results minimally affect US practice patterns so far

Article

According to the results of an online survey conducted by the ASCRS Cataract Clinical Committee, the results of the ESCRS study of endophthalmitis prophylaxis do not appear to have had a significant impact on the practices of US cataract surgeons.

According to the results of an online survey conducted by the ASCRS (American Society of Cataract and Refractive Surgery) Cataract Clinical Committee, the results of the ESCRS (European Society of Cataract and Refractive Surgeons) study of endophthalmitis prophylaxis do not appear to have had a significant impact on the practices of US cataract surgeons, said David F. Chang, MD, at Spotlight on Cataracts 2007.

Open to ASCRS members, the survey was performed in January 2007 and captured about 1,300 responses. The participants were predominantly US surgeons, but represented a broad distribution of surgical volumes.

Of the survey respondents, 16% said they were already using an intracameral antibiotic before the ESCRS study, but only 7% had started based on its results, whereas 77% still were not.

For surgeons using an intracameral antibiotic, vancomycin was the most frequent choice (61%). Among the non-users, the most common reason cited (89%) was a need for further study. However, 45% were concerned about risk and 17% about cost.

When asked whether they would consider an intracameral antibiotic if a product for direct injection was commercially available, 47% said yes and another 35% said they would depending upon the cost.

"One can only speculate why the ESCRS study has not had more of an impact," Dr. Chang said. "The most common practice for antibiotic prophylaxis among the survey participants involved use of a fourth-generation fluoroquinolone started 1 to 3 days preoperatively and continued immediately after surgery. In the ESCRS study, levofloxacin was used and not started until the morning after surgery.

"Therefore, the ESCRS study did not answer whether intracameral cefuroxime is as good as, better than, or useful added to the most commonly used topical antibiotic protocol in this country," he said. "The fact that 82% of respondents indicated they would at least consider using intracameral antibiotics if a product was commercially available is an important message to our partners in industry."

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.